Female Breast Carcinoma
6
0
1
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.7%
1 terminated out of 6 trials
75.0%
-11.5% vs benchmark
17%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
Anesthesia and Circulating Tumor Cells in Breast Cancer
Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography
Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy
The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer